

ACKNOWLEDGEMENTS

BLSA: The BLSA was supported by the Intramural Research Program of the NIH, National Institute on Aging.

BWHHS: The British Women Heart and Health Study is supported by British Heart Foundation programme grant no. PG/13/66/30442 and Department of Health Policy Research Programme (0090049). Genotype analysis in BWHHS was supported by the BHF (PG/07/131/24254) and UK Medical Research Council MC_UU_12013/8.

COLAUS: The CoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (33CSCO-122661). The authors thank Gerard Waeber, Vincent Mooser and Dawn Waterworth, Co-PIs of the CoLaus study. Special thanks to Murielle Bochud, Yolande Barreau, Mathieu Firmann, Vladimir Mayor, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection.

Ely: We are grateful to all the volunteers and to the staff of St. Mary's Street Surgery, Ely and the study team. The Ely Study was funded by the MRC (MC_U106179471) and Diabetes UK. Genotyping in the Ely and Fenland studies was supported in part by an MRC-GlaxoSmithKline pilot programme grant (G0701863).

ERF: The genotyping for the ERF study was supported by EUROSPAN (European Special Populations Research Network) and the European Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study was further supported by grants from the Netherlands Organisation for Scientific Research, Erasmus MC, the Centre for Medical Systems Biology (CMSB) and the Netherlands Brain Foundation (HersenStichting Nederland). We are grateful to all participating individuals and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.

Family Heart Study: The Family Heart Study is funded by a NHLBI grant 5R01HL08770003, and NIDDK grants 5R01DK06833603 and 5R01DK07568102.

Fenland: The Fenland Study is funded by the Wellcome Trust and the Medical Research Council (MC_U106179471). We are grateful to all the volunteers for their time and help, and to the General Practitioners and practice staff for assistance with recruitment. We thank the Fenland Study Investigators, Fenland Study Co-ordination team and the Epidemiology Field, Data and Laboratory teams.

FINRISK97: This study has been funded by the Academy of Finland (grant numbers 139635, 129494, 118065, 129322, 250207, 136895, 263836), the Orion-Farmos Research Foundation, the Finnish Foundation for Cardiovascular Research, and the Sigrid Jusélius Foundation. We are grateful for the THL DNA laboratory for its

skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the samples.

GARP: We thank all participants of the GARP study. The Leiden University Medical Centre, the Dutch Arthritis Association and Pfizer Inc., Groton, CT, USA support the GARP study, whilst genotypic work was supported by the Netherlands Organization of Scientific Research (MW 904-61-095, 911-03-016, 917 66344 and 911-03-012), Leiden University Medical Centre, and by the “Centre of Medical Systems Biology” and the “Netherlands Consortium of Healthy Aging” in the framework of the Netherlands Genomics Initiative (NGI). Furthermore, the research leading to these results has received funding from the Dutch Arthritis Association (DAA 2010_017) and the European Union's Seventh Framework Programme (FP7/2007-2011) under grant agreement n° 259679.

GEMS: We acknowledge GEMS Study Investigators: Philip Barter, PhD; Antero Kesäniemi, PhD; Robert W. Mahley, PhD; Ruth McPherson, FRCP; Gerard Waeber MD; and Scott M. Grundy, PhD.

GLACIER: We thank the participants, health professionals and data managers involved in the Northern Swedish Health and Disease Study. We specifically thank John Hutiaainen and Åsa Ågren (Umeå Medical Biobank) for data organization, and Kerstin Enquist and Thore Johansson (Västerbottens County Council) for expert technical assistance with DNA preparation. The GLACIER Study was funded by project grants from Novo Nordisk, the Swedish Heart-Lung Foundation, the Swedish Diabetes Association, Pålhlssons Foundation, the Swedish Research Council, Umeå University Career Development Award, and The Heart Foundation of Northern Sweden (all to P.W.F). F.R. was supported by a post-doctoral stipend from the Swedish Heart-Lung Foundation.

GOOD: Financial support was received from the Swedish Research Council, the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg's Foundation, the Novo Nordisk Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS.

GOYA: This study was conducted as part of the activities of the Gene-Diet Interactions in Obesity project (GENDINOBO, www.gendinob.dk) and the MRC centre for Causal Analyses in Translational Epidemiology (MRC CAiTE). We thank all the participants of the study. TSA was also funded by the GENDINOBO project and acknowledges the same.

Health2000: This study has been funded by the Academy of Finland (grant numbers 129322 and 250207), the Orion-Farmos Research Foundation, the Finnish Foundation for Cardiovascular Research, and the Sigrid Jusélius Foundation. The Health 2000 Study was funded by the National Institute for Health and Welfare (THL), the Finnish Centre for Pensions (ETK), the Social Insurance Institution of Finland (KELA), the Local Government Pensions Institution (KEVA) and other organizations listed on the website of the survey (<http://www.terveys2000.fi>). We are grateful for the THL DNA laboratory for its skillful work to produce the

DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the GenMets subcohort.

HealthABC: The Health ABC Study was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106 and, in part, by the NIA Intramural Research Program. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (<http://biowulf.nih.gov>).

HBCS: We thank all study participants as well as everybody involved in the Helsinki Birth Cohort Study. Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland (130326, 134791, 263924), the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg Foundation, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation, Finnish Foundation for Pediatric Research, Sigrid Juselius Foundation, the Finnish Special Governmental Subsidy for Health Sciences, Samfundet Folkhälsan, Liv och Hälsa, and Wellcome Trust (grant number WT089062). We are grateful for the THL DNA laboratory for its skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the samples.

HERITAGE: The HERITAGE Family Study is supported by the National Heart, Lung, and Blood Institute Grant HL-45670

InCHIANTI: The InCHIANTI study baseline (1998-2000) was supported as a "targeted project" (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336).

INTER99: The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk). The Inter99 study was initiated by Torben Jørgensen (PI), Knut Borch-Johnsen (co-PI), Hans Ibsen and Troels F. Thomsen. The steering committee comprises the former two and Charlotta Pisinger. The study was financially supported by research grants from the Danish Research Council, the Danish Centre for Health Technology Assessment, Novo Nordisk Inc., Research Foundation of Copenhagen County, Ministry of Internal Affairs and Health, the Danish Heart Foundation, the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation, and the Danish Diabetes Association.

KORA: We thank all members of the field staff involved in the KORA study and we express our appreciation to all study participants. We thank the KORA Study Group consisting of A. Peters (speaker), J. Heinrich, R. Holle, R.

Leidl, C. Meisinger, K. Strauch, and their co-workers, who are responsible for the design and conduct of the KORA studies. The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum München - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ.

LLS: The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2011) under grant agreement number 259679. This study was financially supported by the Innovation-Oriented Research Program on Genomics (SenterNovem IGE05007), the Centre for Medical Systems Biology and the Netherlands Consortium for Healthy Ageing (grant 050-060-810), all in the framework of the Netherlands Genomics Initiative, Netherlands Organization for Scientific Research (NWO), by Unilever Colworth and by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007).

LURIC: We extend our appreciation to the participants of the LURIC study; without their collaboration, this article would not have been written. We thank the LURIC study team who were either temporarily or permanently involved in patient recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen General Hospital and the Universities of Freiburg and Ulm, Germany. This work was supported by the 7th Framework Program (integrated project AtheroRemo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739) of the European Union and, by the INTERREG IV Oberrhein Program (Project A28, Genetic mechanisms of cardiovascular diseases) with support from the European Regional Development Fund (ERDF) and the Wissenschaftsoffensive TMO.

MESA: MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with MESA investigators. Support for MESA is provided by contracts N01-HC-95159 through N01-HC-95169 and UL1-RR-024156. Funding for MESA Family is provided by grants R01-HL-071051, R01-HL-071205, R01-HL-071250, R01-HL-071251, R01-HL-071252, R01-HL-071258, R01-HL-071259, UL1-RR-25005. Funding for genotyping was provided by National Heart, Lung, and Blood Institute contracts N02-HL-6-4278, N01-HC-65226, and HHSN26800625226C. Additional support was provided by grant R01HL088451.

MICROS: For the MICROS study, we thank the primary care practitioners Raffaella Stocker, Stefan Waldner, Toni Pizzocco, Josef Plangger, Ugo Marcadent, and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. The MICROS study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947).

MrOS Sweden: Financial support was received from the Swedish Research Council, the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg's Foundation, the Novo Nordisk Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS.

NHS: This research was supported by NIH grants HG004399, HG004446, CA087969, CA055075, DK058845, CA65725, CA49449, CA67262, CA50385, and UO1CA098233. Qi Sun was supported by a career development award (R00HL098459) from the NHLBI.

PIVUS: APM is a Wellcome Trust Senior Research Fellow and acknowledges funding from the Wellcome Trust under awards WT098017, WT090532 and WT064890. C.M.L. is a Wellcome Trust Research Career Development Fellow (086596/Z/08/Z) and acknowledges funding from the Li Ka Shing Foundation.

PROSPER: The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J. W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810).

RISC: DS acknowledges funding from the Wellcome Trust (grant no 091551).

Rotterdam Study: The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.

TwinsUK: The study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also receives support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas', NHS Foundation Trust and King's College London. Brent Richards is funded by the CIHR, MDEIE, FRSQ and CFI. SNP Genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR.

WGHS: The WGHS is supported by HL043851 and HL080467 from the National Heart, Lung, and Blood Institute and CA047988 from the National Cancer Institute and the Donald W. Reynolds Foundation, with collaborative scientific support and funding for genotyping provided by Amgen. Leptin measures were funded by an investigator-initiated grant from Roche Pharmaceuticals to PMR.

Young Finns: The Young Finns Study has been financially supported by the Academy of Finland: grants 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi), the Social Insurance Institution of Finland, Kuopio, Tampere and Turku University Hospital Medical Funds (grant 9M048 and 9N035 for TeLeht), Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation of Cardiovascular Research and Finnish Cultural Foundation, Tampere Tuberculosis Foundation and Emil Aaltonen Foundation (T.L). We gratefully acknowledge the THL DNA laboratory for its skillful work to produce the DNA samples used in this study, and Ville Aalto and Irina Lisinen for the expert technical assistance in the statistical analyses.

Other acknowledgements: Tuomas O. Kilpeläinen is supported by grant no. DFF - 1333-00124 from the Danish Council for Independent Research. Robert J. Klein was supported by the NHGRI grant U01-HG007033. Data on the childhood obesity trait has been contributed by EGG Consortium and has been downloaded from www.egg-consortium.org. Data on glycaemic traits have been contributed by MAGIC investigators and have been downloaded from www.magicinvestigators.org.